Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,862 across all filing types
Latest filing 2022-01-26 Board/Management Inform…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos appoints Paul Stoffels as Chief Executive Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing a significant change in senior management: the appointment of Dr. Paul Stoffels as the new Chief Executive Officer (CEO), succeeding the co-founder Onno van de Stolpe. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. It is not a full financial report (10-K, IR), an earnings announcement (ER), or a proxy statement (DEF 14A/PSI).
2022-01-26 English
Galapagos benoemt Paul Stoffels tot Chief Executive Officer
Board/Management Information Classification · 100% confidence The document is a press release dated January 26, 2022, announcing a significant change in senior management: the appointment of Dr. Paul Stoffels as the new Chief Executive Officer (CEO), succeeding the founder Onno van de Stolpe upon his planned retirement. This content directly matches the definition for 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2022-01-26 Dutch
6-K Filing
Regulatory Filings
2022-01-26 English
JYSELECA®? (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Regulatory Filings Classification · 95% confidence The document is a press release dated January 18, 2022, announcing that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization for Jyseleca (filgotinib) for ulcerative colitis in Great Britain. This type of announcement, detailing a regulatory decision or key business development (like a drug approval), is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally as a Regulatory Filing (RNS) if it's a broad announcement. However, given the context of a major regulatory milestone announcement that is not a full financial report (like 10-K or IR) and is not specifically about management changes (MANG), dividend (DIV), or capital structure (CAP), it fits best under the general category for significant corporate news that isn't covered by the more specific financial/governance codes. Since it is a direct announcement of a regulatory action impacting the business, and it is not a transcript (CT), investor presentation (IP), or a formal financial report, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, although ER might be considered if financial impact was the focus. Since the focus is purely on the regulatory approval announcement itself, RNS is chosen as the best fit among the available options for a non-financial, non-governance specific press release.
2022-01-19 English
JYSELECA®? (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Regulatory Filings Classification · 90% confidence The document is a press release dated January 18, 2022, announcing that the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain has granted marketing authorization for Jyseleca (filgotinib) for the treatment of adult patients with moderate to severe active ulcerative colitis (CU). This type of announcement, detailing a regulatory approval for a drug indication, is a specific corporate event update. It is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a general Regulatory Filing (RNS). Since it is a specific announcement regarding a key business development (drug approval), it fits best under the general category of corporate news or updates that are not explicitly covered by other codes like M&A (TAR) or Financing (CAP). Given the provided definitions, this is a significant corporate announcement that doesn't map perfectly to the financial reporting codes. However, it is a specific regulatory outcome announcement. Since there is no 'Regulatory Approval Announcement' code, and it is not a financial report, management discussion, or shareholder material, the most appropriate classification among the choices for a significant, non-financial, non-management specific announcement is often the general 'Regulatory Filings' (RNS) or, if it were about management/board changes, MANG. Since this is a positive regulatory outcome announcement, and it is not a short notice about a report being published (RPA), RNS serves as the best general regulatory/corporate news fallback. Given the context of financial reporting databases, these types of announcements are often categorized broadly. I will classify it as RNS as the best fit for a specific regulatory/business update not covered elsewhere.
2022-01-19 English
6-K Filing
Regulatory Filings
2022-01-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.